SG10201907841UA - Adenovirus expressing immune cell stimulatory receptor agonist(s) - Google Patents

Adenovirus expressing immune cell stimulatory receptor agonist(s)

Info

Publication number
SG10201907841UA
SG10201907841UA SG10201907841UA SG10201907841UA SG 10201907841U A SG10201907841U A SG 10201907841UA SG 10201907841U A SG10201907841U A SG 10201907841UA SG 10201907841U A SG10201907841U A SG 10201907841UA
Authority
SG
Singapore
Prior art keywords
receptor agonist
immune cell
cell stimulatory
adenovirus expressing
stimulatory receptor
Prior art date
Application number
Inventor
Frank Tufaro
Juan Fueyo-Margareto
Candelaria Gomez-Manzano
W K Yung
Hong Jiang
Original Assignee
Dnatrix Inc
The Board Of Regents The University Of Texas System
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Dnatrix Inc, The Board Of Regents The University Of Texas System filed Critical Dnatrix Inc
Publication of SG10201907841UA publication Critical patent/SG10201907841UA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/76—Viruses; Subviral particles; Bacteriophages
    • A61K35/761—Adenovirus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/19—Cytokines; Lymphokines; Interferons
    • A61K38/21—Interferons [IFN]
    • A61K38/217—IFN-gamma
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10021—Viruses as such, e.g. new isolates, mutants or their genomic sequences
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
    • C12N2710/00011—Details
    • C12N2710/10011—Adenoviridae
    • C12N2710/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2840/00—Vectors comprising a special translation-regulating system
    • C12N2840/20—Vectors comprising a special translation-regulating system translation of more than one cistron
    • C12N2840/203—Vectors comprising a special translation-regulating system translation of more than one cistron having an IRES

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Microbiology (AREA)
  • Immunology (AREA)
  • Biochemistry (AREA)
  • Wood Science & Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

Certain embodiments include the enhancement of effectiveness for an adenoviral cancer therapy. [Fig.1]
SG10201907841U 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s) SG10201907841UA (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201361907860P 2013-11-22 2013-11-22

Publications (1)

Publication Number Publication Date
SG10201907841UA true SG10201907841UA (en) 2019-10-30

Family

ID=53180213

Family Applications (1)

Application Number Title Priority Date Filing Date
SG10201907841U SG10201907841UA (en) 2013-11-22 2014-11-21 Adenovirus expressing immune cell stimulatory receptor agonist(s)

Country Status (11)

Country Link
US (3) US20160289645A1 (en)
EP (2) EP3071697B1 (en)
JP (3) JP2016540505A (en)
KR (1) KR20160137946A (en)
CN (2) CN106029889A (en)
AU (1) AU2014352749A1 (en)
CA (1) CA2931322A1 (en)
DK (1) DK3071697T3 (en)
ES (1) ES2765489T3 (en)
SG (1) SG10201907841UA (en)
WO (1) WO2015077624A1 (en)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2971008B1 (en) 2013-03-14 2018-07-25 Salk Institute for Biological Studies Oncolytic adenovirus compositions
GB201322851D0 (en) 2013-12-23 2014-02-12 Psioxus Therapeutics Ltd Method
SG11201602887QA (en) 2013-10-25 2016-05-30 Psioxus Therapeutics Ltd Oncolytic adenoviruses armed with heterologous genes
GB201406608D0 (en) 2014-04-12 2014-05-28 Psioxus Therapeutics Ltd Virus
ES2845727T3 (en) * 2015-02-06 2021-07-27 Heat Biologics Inc Vector co-expressing a vaccine and costimulatory molecules
CN108396015B (en) 2015-04-30 2022-02-18 皮斯奥克斯治疗公司 Oncolytic adenovirus encoding B7 protein
MY189692A (en) 2015-05-07 2022-02-26 Memorial Sloan Kettering Cancer Center Anti-ox40 antibodies and methods of use thereof
WO2017070110A1 (en) * 2015-10-19 2017-04-27 Cold Genesys, Inc. Methods of treating solid or lymphatic tumors by combination therapy
MX2018006477A (en) 2015-12-02 2018-09-03 Agenus Inc Antibodies and methods of use thereof.
KR20180107105A (en) 2015-12-17 2018-10-01 싸이오서스 테라퓨틱스 엘티디. A group B adenovirus encoding an anti-TCR-complex antibody or fragment
BR112018013930A2 (en) 2016-01-08 2018-12-11 Replimune Limited oncolytic virus, virus expressing three heterologous genes, pharmaceutical composition, virus for use, manufacturing product, cancer treatment method, and virus use
EP3390428B1 (en) 2016-02-23 2019-09-25 Salk Institute for Biological Studies High throughput assay for measuring adenovirus replication kinetics
KR102471633B1 (en) 2016-02-23 2022-11-25 솔크 인스티튜트 포 바이올로지칼 스터디즈 Exogenous gene expression in therapeutic adenovirus for minimal impact on viral kinetics
JP7208492B2 (en) 2016-03-10 2023-01-19 シージー オンコロジー， インコーポレイテッド Methods of treating solid tumors or lymphoid tumors with combination therapy
WO2017205875A1 (en) * 2016-05-27 2017-11-30 Dnatrix, Inc. Adenovirus and immunomodulator combination therapy
GB201713765D0 (en) 2017-08-28 2017-10-11 Psioxus Therapeutics Ltd Modified adenovirus
PL3293201T3 (en) 2016-09-12 2021-06-14 Targovax Oy Combining adenovirus and checkpoint inhibitors for treating cancer
AU2017359467A1 (en) 2016-11-09 2019-05-02 Agenus Inc. Anti-OX40 antibodies, anti-GITR antibodies, and methods of use thereof
AU2017375633C1 (en) 2016-12-12 2023-04-27 Salk Institute For Biological Studies Tumor-targeting synthetic adenoviruses and uses thereof
EP3551226A1 (en) * 2016-12-12 2019-10-16 MultiVir Inc. Methods and compositions comprising viral gene therapy and an immune checkpoint inhibitor for treatment and prevention of cancer and infectious diseases
US11298420B2 (en) * 2016-12-21 2022-04-12 Memgen, Llc Armed oncolytic viruses
WO2018118967A1 (en) 2016-12-21 2018-06-28 Memgen, Llc Armed replication-competent oncolytic adenoviruses
CN108338994A (en) * 2017-01-25 2018-07-31 杭州康万达医药科技有限公司 Application of the oncolytic virus as the immunostimulant for treating tumour and/or cancer
US11548930B2 (en) 2017-04-04 2023-01-10 Heat Biologics, Inc. Intratumoral vaccination
WO2018191654A1 (en) 2017-04-14 2018-10-18 Cold Genesys, Inc. Methods of treating bladder cancer
CN109276580B (en) * 2017-07-21 2021-08-24 厦门大学 A virus for treating tumor
CN111491655A (en) 2017-08-07 2020-08-04 加利福尼亚大学董事会 Platform for generating safe cell therapeutics
CN107952069A (en) * 2017-11-24 2018-04-24 长春百克生物科技股份公司 Recombinant vaccine and its application
CN109985241A (en) * 2017-12-29 2019-07-09 广州威溶特医药科技有限公司 CDK inhibitor and oncolytic virus are in the application for preparing anti-tumor drug
US20210015878A1 (en) * 2018-03-28 2021-01-21 Epicentrx, Inc. Personalized cancer vaccines
WO2020047345A1 (en) 2018-08-31 2020-03-05 Yale University Compositions and methods of using cell-penetrating antibodies in combination with immune checkpoint modulators
CN116162654A (en) 2018-09-15 2023-05-26 纪念斯隆凯特琳癌症中心 Recombinant poxviruses for cancer immunotherapy
TW202043256A (en) 2019-01-10 2020-12-01 美商健生生物科技公司 Prostate neoantigens and their uses
EP3927833A4 (en) * 2019-02-21 2022-11-30 Unleash Immuno Oncolytics, Inc. Oncolytic adenoviral vector and methods of use
WO2021024207A1 (en) 2019-08-05 2021-02-11 Mesoblast International Sarl Cellular compositions comprising viral vectors and methods of treatment
CN110859968A (en) * 2019-11-21 2020-03-06 四川安可康生物医药有限公司 Genetic biopharmaceuticals to activate systemic immune response to tumors
WO2021252496A1 (en) * 2020-06-10 2021-12-16 Richard Lowenthal Engineered adenovirus vectors and uses thereof
CN115996735A (en) 2020-08-10 2023-04-21 迈索布拉斯特国际有限公司 Cell compositions and methods of treatment
JP2023031503A (en) 2021-08-25 2023-03-09 三菱重工航空エンジン株式会社 Combustor panel, and combustor for gas turbine
WO2024081736A2 (en) 2022-10-11 2024-04-18 Yale University Compositions and methods of using cell-penetrating antibodies

Family Cites Families (30)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4683202A (en) 1985-03-28 1987-07-28 Cetus Corporation Process for amplifying nucleic acid sequences
US5981725A (en) 1989-09-08 1999-11-09 The Johns Hopkins Univiersity Structural alterations of the EGF receptor gene in human tumors
DE4228457A1 (en) 1992-08-27 1994-04-28 Beiersdorf Ag Production of heterodimeric PDGF-AB using a bicistronic vector system in mammalian cells
US7252989B1 (en) 1994-04-04 2007-08-07 Board Of Regents, The University Of Texas System Adenovirus supervector system
FR2722208B1 (en) 1994-07-05 1996-10-04 Inst Nat Sante Rech Med NEW INTERNAL RIBOSOME ENTRY SITE, VECTOR CONTAINING SAME AND THERAPEUTIC USE
AU5551996A (en) 1995-04-17 1996-11-07 Board Of Regents, The University Of Texas System An adenovirus helper-virus system
US5928906A (en) 1996-05-09 1999-07-27 Sequenom, Inc. Process for direct sequencing during template amplification
AU750358B2 (en) * 1997-12-02 2002-07-18 Medarex, Inc. Cells expressing anti-Fc receptor binding components
US6312700B1 (en) 1998-02-24 2001-11-06 Andrew D. Weinberg Method for enhancing an antigen specific immune response with OX-40L
US7368527B2 (en) * 1999-03-12 2008-05-06 Human Genome Sciences, Inc. HADDE71 polypeptides
US20030138405A1 (en) 2001-04-17 2003-07-24 Juan Fueyo Conditionally replicative adenovirus to target the Rb and Rb-related pathways
EP1470233A1 (en) * 2002-02-01 2004-10-27 Transgene S.A. Adenoviral vectors for modulating the cellular activities associated with pods
CA2489004C (en) 2002-06-13 2013-01-08 Crucell Holland B.V. Agonistic binding molecules to the human ox40 receptor
US7291331B1 (en) 2002-09-11 2007-11-06 La Jolla Institute For Allergy And Immunology Methods of treating OX40 medicated recall immune responses
CN102675462A (en) 2003-06-27 2012-09-19 艾默根佛蒙特有限公司 Antibodies directed to the deletion mutants of epidermal growth factor receptor and uses thereof
WO2005086922A2 (en) 2004-03-10 2005-09-22 Board Of Regents, University Of Texas System Oncolytic adenovirus armed with therapeutic genes
KR101379364B1 (en) * 2005-02-08 2014-03-31 보드 오브 리전츠, 더 유니버시티 오브 텍사스 시스템 Compositions involving MDA-7 for the treatment of cancer
DK1877090T3 (en) 2005-05-06 2014-04-14 Providence Health System TRIMED OX40-IMMUNOGLOBULIN FUSION PROTEIN AND METHODS FOR USING IT
SI2161336T1 (en) 2005-05-09 2013-11-29 Ono Pharmaceutical Co., Ltd. Human monoclonal antibodies to programmed death 1(PD-1) and methods for treating cancer using anti-PD-1 antibodies alone or in combination with other immunotherapeutics
ES2304281B1 (en) * 2006-02-01 2009-08-12 Dnatrix Inc. ADENOVIRUS ONCOLITICOS FOR THE TREATMENT OF CANCER.
CN101663323A (en) 2006-12-27 2010-03-03 埃默里大学 The composition and the method that are used for the treatment of transmissible disease and tumour
US20110223188A1 (en) 2008-08-25 2011-09-15 Solomon Langermann Targeted costimulatory polypeptides and methods of use to treat cancer
CN102575227A (en) * 2008-10-08 2012-07-11 英特瑞克斯顿股份有限公司 Engineered cells expressing multiple immunomodulators and uses thereof
KR20210060670A (en) 2008-12-09 2021-05-26 제넨테크, 인크. Anti-pd-l1 antibodies and their use to enhance t-cell function
CN103221427B (en) * 2010-08-23 2016-08-24 德克萨斯州立大学董事会 Anti-OX40 antibody and the method using it
JP2013541945A (en) * 2010-09-24 2013-11-21 オンコス セラピュティックス オサケ ユキチュア Oncolytic adenoviral vectors and related methods and uses
EP3187603A1 (en) * 2011-02-17 2017-07-05 Arconic Inc. 2xxx series aluminum lithium alloys
US11149254B2 (en) * 2011-04-15 2021-10-19 Genelux Corporation Clonal strains of attenuated vaccinia viruses and methods of use thereof
KR102081567B1 (en) * 2012-01-25 2020-02-26 디엔에이트릭스, 인코포레이티드 Biomarkers and combination therapies using oncolytic virus and immunomodulation
CA2863523A1 (en) * 2012-02-02 2013-08-08 Juan FUEYO-MARGARETO Recombinant adenovirus expressing cancer antigens

Also Published As

Publication number Publication date
WO2015077624A1 (en) 2015-05-28
EP3653714A1 (en) 2020-05-20
EP3071697A4 (en) 2017-05-17
ES2765489T3 (en) 2020-06-09
US20160289645A1 (en) 2016-10-06
CN114317461A (en) 2022-04-12
JP2016540505A (en) 2016-12-28
JP2020048582A (en) 2020-04-02
KR20160137946A (en) 2016-12-02
DK3071697T3 (en) 2020-01-27
CA2931322A1 (en) 2015-05-28
JP2021137029A (en) 2021-09-16
US20210301264A1 (en) 2021-09-30
EP3071697A1 (en) 2016-09-28
EP3071697B1 (en) 2019-10-16
AU2014352749A1 (en) 2016-06-09
CN106029889A (en) 2016-10-12
US20190093085A1 (en) 2019-03-28

Similar Documents

Publication Publication Date Title
SG10201907841UA (en) Adenovirus expressing immune cell stimulatory receptor agonist(s)
ZA201907607B (en) Labeled inhibitors of prostate specific membrane antigen (psma), their use as imaging agents and pharmaceutical agents for the treatment of prostate cancer
MY191169A (en) Anti-fcrh5 antibodies
HK1225998A1 (en) Compositions comprising anti-ceacam1 and anti-pd antibodies for cancer therapy
PH12015501954A1 (en) Anti-b7-h4 antibodies and immunoconjugates
PH12016500482A1 (en) Combination therapy with an anti-ang2 antibody and a cd40 agonist
NZ731467A (en) Anti-tim3 antibodies and methods of use
MX2021002728A (en) Combination of anti-lag-3 antibodies and anti-pd-1 antibodies to treat tumors.
MX2017001458A (en) Region-based sizing and positioning of application windows.
AU357122S (en) Headgear for patient interface
PH12015501071A1 (en) Combination therapy of anti-her3 antibodies
PH12020500225A1 (en) Anti- cd137 antibodies
MX356107B (en) Histidyl-trna synthetases for treating autoimmune and inflammatory diseases.
PH12016500316A1 (en) Improved adenovirus formulations
MX366804B (en) R-spondin translocations and methods using the same.
MX2015012326A (en) Anti-crth2 antibodies and their use.
IN2014DN05885A (en)
WO2014134084A3 (en) Phf20 and jmjd3 compositions and methods of use in cancer immunotherapy
MX2016015163A (en) Mit biomarkers and methods using the same.
MX357675B (en) Anti-jagged anitbodies and methods of use.
MX2016005285A (en) Conjugates of somatostatin and its analogs.
EP3030268A4 (en) Combination of ifn-gamma with anti-erbb antibody for the treatment of cancers
PT2978402T (en) Stabilized polyribonucleotide coding for an elastic fibrous protein
NZ631749A (en) Methods of treating cancer using angiogenin or an angiogenin agonist
AU2013342779A8 (en) Anti-ADAM28 antibody for treating cancer